Previous 10 | Next 10 |
Morgan Stanley has initiated Halozyme Therapeutics ( NASDAQ: HALO ) at overweight citing the company's Enhanze technology used for subcutaneous administration of therapies that is licensed to companies. The firm has a $65 price target (~15% upside based on Tuesday's close). Analys...
Halozyme (HALO) has always had a story that’s easy to love, as its Enhanze drug delivery technology allows huge-selling treatments to be delivered intravenously in far less time than usual, saving tons of time, money and adding convenience, too, explains Mike Cintolo, editor of Cabot Growt...
S&P 500 is breathing a much-awaited sigh of relief after the monthly inflation data came in better than expected ( read more ). But there’s hardly a reason to believe that it’s not just another one of the bear market rallies, says Dutch Masters – the Fou...
Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that members of its management team are scheduled to present and host inv...
Halozyme Therapeutics, Inc. (HALO) Q3 2022 Earnings Conference Call November 08, 2022 04:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communication Helen Torley - President & Chief Executive Officer Nicole LaBros...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2022 Q3 - Results - Earnings Call Presentation
Halozyme Therapeutics press release ( NASDAQ: HALO ): Q3 Non-GAAP EPS of $0.74 beats by $0.23 . Revenue of $208.98M (+80.4% Y/Y) beats by $17.81M . FY2022 Outlook : Total revenue of $655M to $685M vs. consensus of $661.35M; GAAP operating income of $24...
HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS PR Newswire Third Quarter Revenue Increased 80% YOY to $209 Million , with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.74 1 Record Thi...
Halozyme to Report Third Quarter 2022 Financial and Operating Results PR Newswire SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operat...
Summary Halozyme made a smooth transition from a failed R&D company to a successful royalty company. Their Antares acquisition is a bid to delay ENHANZE IP expiry, although the autoinjector platform is no real replacement for ENHANZE. However, for the next few years, HALO ...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...